The panel "The Art of the Deal, Why Some Biotechs Get It and Others Don’t" will examine how biotech fundraising and partnering decisions are actually made, looking at how subjects such as data quality, team credibility, market timing, and risk tolerance influence capital allocation from the perspectives of CEOs, VCs, potential partners and media.
Monday, May 4, 17:30 - 18:15, room Shanghai 1+2
| Name | Position | Institution |
|---|---|---|
| Richard Jarvis | Partner | Cohesion Bureau |
| Name | Position | Institution |
|---|---|---|
| Eric Falcand | ||
| Biotech VC | TBA | |
| Corporate VC | TBA |
Cohesion Bureau is a strategic consultancy dedicated to accelerating growth for life sciences companies. Our transatlantic team - US, EU, UK, & Switzerland - brings experience from investing, banking, industry, science, and media. We help biotech and medtech companies shape compelling equity stories and fundraise, and strengthen relationships with investors, partners and media. We support companies from seed stage to post-Nasdaq listing, enhancing visibility, credibility and long-term positioning.
